

DAFTAR PUSTAKA

1. Wang Y, Huang D, Xu WY, Wang YW, Che GW. Prognostic Value of Pretreatment Lymphocyte-to-Monocyte Ratio in Non-Small Cell Lung Cancer: A Meta-Analysis. *Oncol Res Treat*. 2019;42(10):523–30.
2. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, Version 2.2021 featured updates to the NCCN guidelines. *JNCCN J Natl Compr Cancer Netw*. 2021;19(3):254–66.
3. Lim JU, Yeo CD, Kang HS, Park CK, Kim JS, Kim JW, et al. Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion. *PLoS One*. 2018;13(7):1–13.
4. Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, et al. Non-small-cell lung cancer. *Nat Rev Dis Prim*. 2015;1:1–16.
5. Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. *Mayo Clin Proc [Internet]*. 2019;94(8):1623–40. Available from: <https://doi.org/10.1016/j.mayocp.2019.01.013>
6. Soetandyo N, Hanafi AR, Agustini S, Sinulingga DT. Prognosis of advanced stage non-small-cell lung cancer patients receiving chemotherapy: Adenocarcinoma versus squamous cell carcinoma. *Med J Indones*. 2020;29(1):26–31.
7. Zappa C, Mousa SA. Non-small cell lung cancer: Current treatment and future advances. *Transl Lung Cancer Res*. 2016;5(3):288–300.
8. Carbone DP, Gandara DR, Antonia SJ, Zielinski C, Paz-Ares L. Non-small-cell lung cancer: Role of the immune system and potential for immunotherapy. *J Thorac Oncol [Internet]*. 2015;10(7):974–84. Available from: <http://dx.doi.org/10.1097/JTO.0000000000000551>
9. Orakpoghenor O, Avazi DO, Markus T, Olaolu O. Lymphocytes : A Brief Review -. 2019;(June).
10. Kratoofil RM, Kubes P, Deniset JF. Monocyte conversion during inflammation and injury. *Arterioscler Thromb Vasc Biol*. 2017;37(1):35–42.
11. Retnoningrum D, AP P. MONOCYTE LYMPHOCYTE RATIO IN MALIGNANCY. *Clin Pathol Med Lab*. 2017;23(2):111–3.
12. Syahrudin E, Hudoyo A, Arief N. Efusi pleura ganas pada kanker paru. *J Respir Indo*. 2009;29:1–9.
13. Reck M, Rabe KF. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. *N Engl J Med*. 2017;377(9):849–61.
14. Swanton C, Govindan R. Clinical Implications of Genomic Discoveries in Lung Cancer. *N Engl J Med*. 2016;374(19):1864-73.

15. Domagala-Kulawik J OI, Haser G. Mechanisms of Immune Response Regulation in Lung Cancer. *Transl Lung Cancer*. 2014;3(1):15-22.
16. Shintani Y, Maeda M, Chaika N, Johnson KR, Wheelock MJ. Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor- β signaling. *American journal of respiratory cell and molecular biology*. 2008;38(1):95-104.
17. Wynder EL, Hoffmann D. Smoking and lung cancer: scientific challenges and opportunities. *Cancer Research*. 1994;54(20):5284-94.
18. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. *International journal of cancer*. 2002;97(1):72-81.
19. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. *J Pathol*. 2002;196:254–265.
20. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. *Cell*. 2006;124:263–266.
21. Zhang, Bin; Zhang, Lianmin; Yue, Dongsheng; Li, Chenguang; Zhang, Hua; Ye, Junyi; Gao, Liuwei; Zhao, Xiaoliang; Chen, Chen; Huo, Yansong; Pang, Chong; Li, Yue; Chen, Yulong; Chuai, Shannon; Zhang, Zhenfa; Giaccone, Giuseppe; Wang, Changli. Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis. *Translational Lung Cancer Research*, 2020. 9(4), 1187–1201. doi:10.21037/tlcr-19-664
22. Clark SB, Alsubait S. Non Small Cell Lung Cancer. [Updated 2021 Sep 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK562307/>
23. Zang EA. Re: sex, smoking, and cancer: a reappraisal. *Journal of the National Cancer Institute*. 2002 Feb 20;94(4):308-9; author reply 9-10. PubMed PMID: 11854395.
24. Dana H Putra et al. Profil Penderita Kanker Paru Karsinoma Bukan Sel Kecil (KPKBSK) di RSUD Dr. Soetomo. 2016
25. Bhaskarapillai B, Kumar SS, Balasubramanian S. Lung cancer in Malabar Cancer Center in Kerala--a descriptive analysis. *Asian Pac J Cancer Prev*. 2012;13(9):4639-43. doi: 10.7314/apjcp.2012.13.9.4639. PMID: 23167394.
26. Bosaeus, I., Daneryd, P., Svanberg, E., Lundholm, K., Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. *Internasional journal of cancer*, 2001 (93), 380-383.
27. Risnawati et al. Nutrisi pada Penderita Kanker Paru. *Jurnal Respirasi (JR)*, Vol. 5. No. 3 September 2019: 91-100
28. Badan pusat statistik. *Rokok dan kemiskinan*. 2019

29. Toyoda Y, Loka A, Nakayama T, Tsukuma H. Trend in lung cancer incidences by histological types in Osaka, Japan. *Jpn J Clin Oncol* 2008;38:534-539.
30. J.Liu, W.Lee, Z.Jiang, Z.Chen, S.Jhunhunwala, P.M.Haverty, F.Gnad, Y.Guan, H.N. Gilbert, J. Stinson, C. Klijn, J. Guillory, D. Bhatt, S. Vartanian, K. Walter, J. Chan, T. Holcomb, P. Dijkgraaf, S. Johnson, J. Koeman, J.D. Minna, A.F. Gazdar, H.M. Stern, K.P. Hoeflich, T.D. Wu, J. Settleman, F.J. de Sauvage, R.C. Gentleman, R.M. Neve, D. Stokoe, Z. Modrusan, S. Seshagiri, D.S. Shames, Z. Zhang, Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events, *Genome Res.* 22 (2012) 2315–2327.
31. Agatawa Ewa Dutkowska et al., Comorbidities in lung cancer. *Pneumonol Alergol Pol* 2016; 84: 186-192
32. SHOLL, Lynette M. Biomarkers in lung adenocarcinoma: a decade of progress. *Archives of Pathology and Laboratory Medicine*, 2015, 139.4: 469-480.
33. West H, Jin JO. Performance Status in Patients With Cancer. *JAMA Oncol.* 2015;1(7):998. doi:10.1001/jamaoncol.2015.3113
34. Sehgal K, Gill RR, Widick P, et al. Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. *JAMA Netw Open.* 2021;4(2):e2037120. doi:10.1001/jamanetworkopen.2020.37120
35. Azzoli, C. G.; Baker, S.; Temin, S.; Pao, W.; Aliff, T.; Brahmer, J.; Johnson, D. H.; Laskin, J. L.; Masters, G.; Milton, D.; Nordquist, L.; Pfister, D. G.; Piantadosi, S.; Schiller, J. H.; Smith, R.; Smith, T. J.; Strawn, J. R.; Trent, D.; Giaccone, G. (2009). American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, 27(36), 6251–6266. doi:10.1200/jco.2009.23.5622
36. Deng YX, Lin JZ, Peng JH, et al. Lymphocyte-to-monocyte ratio before chemoradiotherapy represents a prognostic predictor for locally advanced rectal cancer. *Onco Targets Ther* 2017;10:5575–83.
37. Lee SF, Luque-Fernandez MA. Prognostic value of lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio in follicular lymphoma: a retrospective cohort study. *BMJ Open* 2017;7:e017904.
38. Chen Y, Wang W, Zhang X, Yu X, Xi K, Wen Y, Wang G, Feng X, Zhang L. Prognostic significance of combined preoperative platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients undergoing surgery with stage IB non-small-cell lung cancer. *Cancer Manag Res.* 2018;10:5411–22.
39. Ramos, R., Macía, I., Navarro-Martin, A. et al. Prognostic value of the preoperative lymphocyte-to-monocyte ratio for survival after lung

- cancer surgery. *BMC Pulm Med* 21, 75 (2021).
<https://doi.org/10.1186/s12890-021-01446-1>
40. Zhang, Y., Feng, Y. C., Zhu, H. G., Xiong, T. C., Hou, Y. S., Song, J., Jiang, W., & Zhu, C. J. (2018). The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs. *Medicine*, 97(30), e11648.
<https://doi.org/10.1097/MD.00000000000011648>
 41. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144(5):646–74.
 42. Chen L, Zhang F, Sheng XG, Zhang SQ. Decreased pretreatment lymphocyte/monocyte ratio is associated with poor prognosis in stage Ib1–IIa cervical cancer patients who undergo radical surgery. *Onco Targets Ther*. 2015;8(8):1355–62.
 43. Krstic J, Santibanez JF. Transforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma infiltrating myeloid cells. *Sci World J*. 2014;2014:521754.
 44. Sarode P, Schaefer MB, Grimminger F, Seeger W, Savai R. Macrophage and tumor cell cross-talk is fundamental for lung tumor progression: we need to talk. *Front Oncol*. 2020;10(324):1–11.
 45. Feng F, Zheng G, Wang Q, Liu S, Liu Z, Xu G, Wang F, Guo M, Lian X, Zhang H. Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer. *BMC Gastroenterol*. 2018;18(1):148.
 46. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA (2014) Chronic Inflammation and Cytokines in the Tumor Microenvironment. *J Immunol Res* 2014: 149185.
 47. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? *Lancet* 357: 539–545.
 48. Bishara S, Griffin M, Cargill A, Bali A, Gore ME, et al. (2008) Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer. *Eur J Obstet Gynecol Reprod Biol* 138: 71–75.
 49. Botta C, Barbieri V, Ciliberto D, Rossi A, Rocco D, et al. (2013) Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. *Cancer Biol Ther* 14: 469–475.
 50. Haruki K, Shiba H, Fujiwara Y, Furukawa K, Wakiyama S, et al. (2012) Perioperative change in peripheral blood monocyte count may predict prognosis in patients with colorectal liver metastasis after hepatic resection. *J Surg Oncol* 106: 31–35.
 51. Lee YY, Choi CH, Sung CO, Do IG, Huh S, et al. (2012) Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level. *Gynecol Oncol* 124:92–97.
 52. Stotz M, Pichler M, Absenger G, Szkandera J, Armingier F, et al. (2014) The preoperative lymphocyte to monocyte ratio predicts

clinical outcome in patients with stage III colon cancer. *Br J Cancer* 110: 435–440.

53. Li J, Jiang R, Liu WS, Liu Q, Xu M, et al. (2013) A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma. *PLoS One* 8: e83069.